Determining Dosing Intervals for Luteinizing Hormone Releasing Hormone Agonists Based on Serum Testosterone Levels: A Prospective Study

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 2132-2135

  Pathak, Apurba S ^a   Pacificar, Judy S ^a   Shapiro, Charles E ^a   Williams, Stephen G ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

gonadotropin releasing hormone; prostatic neoplasms; testosterone

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER THERAPY; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HORMONAL THERAPY; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 34248191736     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.157     Document Type: Article

References (14)

1. Huggins C., and Hodges C.V. Studies on prostate cancer: effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293
2. Oefelein M.G., and Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (2000) 726
3. Oefelein M.G. The duration of action after 3 month luteinizing hormone-releasing hormone (LH-RH) agonist chronically administered in men with advanced stage prostate cancer: a phase II assessment. J Urol 161 suppl. (1999) 296 abstract 1139
4. Sharifi R., Bruskewitz R.C., Gittleman M.C., Graham Jr. S.D., Hudson P.B., and Stein B. Leuprolide acetate 22.5 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 18 (1996) 647
5. Lam J.S., Leppert J.T., Vemulapalli S.N., Shvarts O., and Belldegrun A.S. Secondary hormonal therapy for advanced prostate cancer. J Urol 175 (2006) 27
6. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 160 (1998) 1685
7. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer Statistics, 2005. CA Cancer J Clin 55 (2005) 10
8. Oefelein M.G. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 169 (2003) 251
9. Wechsel H.W., Zerbib M., Pagano F., and Coptcoat M.J. Randomized open labeled comparative study of the efficacy, safety and tolerability of leuprorelin acetate IM and 3M depot in patients with advanced prostatic cancer. Eur Urol 30 (1996) 7
10. Debruyne F.M., Dijkman F.A., Lee D.C., Witjes W.P., del Moral F., Karthaus H.F., et al. A new long acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin: results of studies in prostate cancer. J Urol 155 (1996) 1352
11. Vogelzang N.J., Chodak G.W., Soloway M.S., Block N.L., Schellhammer P.F., Smith Jr. J.A., et al., Zoladex Prostate Study Group. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: a randomized trial. Urology 46 (1995) 220
12. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238
13. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 1 (2005) 4653
14. Page S.T., Lin D.W., Mostaghel E.A., Hess D.L., True L.D., and Amory J.K. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91 (2006) 3850